COVID-19 Vaccination Improves Survival in Patients with Cancer Receiving Immunotherapy

An Intriguing Finding

• The COVID-19 pandemic prompted new treatment approaches, particularly in diseases such as cancer, in which the immune system is critical.
• Recent research in this context has published new data indicating that mRNA-based COVID-19 vaccines not only provide protection against SARS-CoV-2 but also, in patients with cancer receiving immunotherapies from the immune checkpoint inhibitor class , increase survival rates .
• How is this possible? In light of new findings presented at the ESMO Congress 2024, this article focuses on the role of mRNA COVID-19 vaccines in cancer treatment through increasing PD-L1 expression —involving immune-regulating molecules on the cell surface—and the implications of these findings for clinical practice.

mRNA COVID-19 Vaccination and PD-L1: Potential Effects in Cancer Treatment

mRNA COVID-19 vaccines are known to increase PD-L1 (Programmed Cell Death Ligand 1) expression, particularly in patients receiving immunotherapies. PD-L1 is a mechanism that allows tumor cells to evade the immune system , and treatments targeting PD-L1 expression have revolutionized cancer care.

The mechanism of action of immune checkpoint inhibitor immunotherapies is illustrated simply below:

The Study Presented at ESMO 2024

The new study presented by Dr. Adam J. Grippin and colleagues suggests that mRNA COVID-19 vaccines increase PD-L1 expression in patients receiving immunotherapy, enabling more effective recognition of tumors by the immune system . It focused particularly on challenging cancers such as non-small cell lung cancer (NSCLC) and metastatic melanoma .

The study observed higher immunotherapy response rates and significantly improved survival in patients with cancer who received an mRNA COVID-19 vaccine within 100 days.

Promising Results in Lung Cancer and Melanoma

PD-L1 expression was examined in 2358 patients with stage 3-4 non-small cell lung cancer, revealing differences according to vaccination timing.

In particular, mRNA COVID-19 vaccination within the first 100 days significantly increased the PD-L1 tumor proportion score (TPS). The proportion of patients with TPS above 50% was 33% among those vaccinated within 100 days, 24% among those vaccinated more than 100 days earlier, and 28% among those never vaccinated. Among patients with PD-L1 TPS above 1%, the respective proportions were 74%, 67%, and 68%.

These findings suggest that mRNA COVID-19 vaccines have a distinctive biological effect in cancer treatment.

Similar results were obtained in patients with metastatic melanoma. Overall survival was significantly higher in patients vaccinated within 100 days before starting immunotherapy than in unvaccinated patients (HR 0.31; 95% CI, 0.16-0.57). Progression-free survival also improved significantly (HR 0.61; 95% CI, 0.39-0.95).

Why Are mRNA Vaccines Different? Comparison with Other Vaccines

An important finding was that increased PD-L1 expression occurred with mRNA vaccines alone , while other vaccines, such as pneumonia or influenza vaccines, did not produce a similar effect. Dr. Grippin notes that this may indicate a unique biological effect of mRNA vaccines in cancer. In this context, it is suggested that mRNA vaccines may not only protect patients with cancer against infections but also strengthen their immune system's ability to fight cancer.

Improved Survival Rates: What Do the Numbers Say?

The findings show significantly improved overall survival rates among vaccinated patients with cancer. In lung cancer, survival rates were 48% higher in patients receiving an mRNA COVID-19 vaccine than in unvaccinated patients (HR 0.52; 95% CI, 0.37-0.72). This figure reached 54% in stage III lung cancer (HR 0.46; 95% CI, 0.31-0.70), while a 28% improvement was observed in stage IV disease (HR 0.72; 95% CI, 0.59-0.88).

Similarly, vaccination had a significant effect in patients with metastatic melanoma. Their overall survival rates were 69% better than those of unvaccinated patients (HR 0.31; 95% CI, 0.16-0.57).

Future Research and Clinical Implications

Because this study was retrospective, the findings need support from prospective research. However, current data strongly suggest that mRNA COVID-19 vaccines may enhance treatment response, particularly in patients with cancer receiving immune checkpoint inhibitors. Dr. Grippin and colleagues emphasize the need to confirm these findings in larger and more diverse patient groups. Deeper investigation of vaccination timing and biological effects in cancer treatment, in particular, has the potential to improve survival in the future.

Conclusion: The Groundbreaking Role of mRNA Vaccines in Cancer Treatment

This study shows that mRNA-based COVID-19 vaccines may not only protect against the pandemic but also make a new difference in cancer treatment. Improved survival and increased PD-L1 expression in patients receiving immunotherapy reveal the powerful effects of mRNA vaccines on the immune system. These findings clearly indicate a need to reconsider vaccination strategies in cancer care and pursue future research in this direction.